Yuan Ye, Du Weijie, Liu Jiaqi, Ma Wenya, Zhang Lai, Du Zhimin, Cai Benzhi
Department of Clinical Pharmacy, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Department of Pharmacology, College of Pharmacy, Harbin Medical University, Harbin, China.
Front Pharmacol. 2018 May 31;9:547. doi: 10.3389/fphar.2018.00547. eCollection 2018.
The stem cell-based therapy has emerged as the promising therapeutic strategies for cardiovascular diseases (CVDs). Recently, increasing evidence suggest stem cell-derived active exosomes are important communicators among cells in the heart via delivering specific substances to the adjacent/distant target cells. These exosomes and their contents such as certain proteins, miRNAs and lncRNAs exhibit huge beneficial effects on preventing heart damage and promoting cardiac repair. More importantly, stem cell-derived exosomes are more effective and safer than stem cell transplantation. Therefore, administration of stem cell-derived exosomes will expectantly be an alternative stem cell-based therapy for the treatment of CVDs. Furthermore, modification of stem cell-derived exosomes or artificial synthesis of exosomes will be the new therapeutic tools for CVDs in the future. In addition, stem cell-derived exosomes also have been implicated in the diagnosis and prognosis of CVDs. In this review, we summarize the current advances of stem cell-derived exosome-based treatment and prognosis for CVDs, including their potential benefits, underlying mechanisms and limitations, which will provide novel insights of exosomes as a new tool in clinical therapeutic translation in the future.
基于干细胞的疗法已成为治疗心血管疾病(CVDs)的有前景的治疗策略。最近,越来越多的证据表明,干细胞衍生的活性外泌体通过向相邻/远处靶细胞传递特定物质,是心脏细胞间重要的通讯介质。这些外泌体及其所含物质,如某些蛋白质、微小RNA(miRNAs)和长链非编码RNA(lncRNAs),在预防心脏损伤和促进心脏修复方面显示出巨大的有益作用。更重要的是,干细胞衍生的外泌体比干细胞移植更有效、更安全。因此,给予干细胞衍生的外泌体有望成为一种基于干细胞的替代疗法来治疗CVDs。此外,对干细胞衍生外泌体进行修饰或人工合成外泌体将是未来治疗CVDs的新治疗工具。此外,干细胞衍生的外泌体也与CVDs的诊断和预后有关。在本综述中,我们总结了基于干细胞衍生外泌体治疗和预测CVDs的当前进展,包括它们的潜在益处、潜在机制和局限性,这将为外泌体作为未来临床治疗转化的新工具提供新的见解。